維帕他韋

{{Drugbox
| Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = Methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)-2-pyrrolidinyl]-1H-imidazol-4-yl}-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methyl-1-pyrrolidinyl]-3-methyl-1-oxo-2-butanyl}carbamate
| image = Velpatasvir.svg
| image_class = skin-invert-image
| width = 275

| tradename = Epclusa、Sofosvel,與Velpanat (均與索磷布韋共同組成複方藥）
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| licence_EU =
| legal_AU =
| legal_CA =
| legal_UK =
| legal_US = Rx-only
| legal_status =
| routes_of_administration = 口服給藥 (片劑)

| bioavailability =
| protein_bound = >99.5%
| metabolism = 肝臟 (CYP2B6, , CYP3A4)
| elimination_half-life = 15小時
| excretion = 糞便 (94%), 尿液 (0.4%)

| CAS_number_Ref =
| CAS_number = 1377049-84-7
| ATC_prefix = J05
| ATC_suffix = AP55
| ATC_supplemental = (索磷布韋/維帕他韋)
()
| PubChem = 67683363
| DrugBank_Ref =
| DrugBank = DB11613
| ChemSpiderID = 34501056
| ChEBI_Ref =
| ChEBI = 133009
| ChEMBL =
| UNII_Ref =
| UNII = KCU0C7RS7Z
| KEGG = D10806

| C=49 | H=54 | N=8 | O=8
| molecular_weight =
| smiles = COC[C@H]1CC@@HCOc3cc5c(ccc6[nH]c([C@@H]7CCC@HN7C(=O)C@@HOC)C(C)C)nc65)cc3-4)[nH]2)N(C(=O)C@HOC)c2ccccc2)C1
| StdInChI = 1S/C49H54N8O8/c1-26(2)41(54-48(60)63-5)47(59)57-27(3)12-17-38(57)45-51-36-16-14-30-20-35-33-15-13-31(19-32(33)25-65-40(35)21-34(30)43(36)53-45)37-22-50-44(52-37)39-18-28(24-62-4)23-56(39)46(58)42(55-49(61)64-6)29-10-8-7-9-11-29/h7-11,13-16,19-22,26-28,38-39,41-42H,12,17-18,23-25H2,1-6H3,(H,50,52)(H,51,53)(H,54,60)(H,55,61)/t27-,28-,38-,39-,41-,42+/m0/s1
| StdInChIKey = FHCUMDQMBHQXKK-CDIODLITSA-N
| synonyms =
}}

維帕他韋（INN:velpatasvir）是一種由吉利德科學製藥開發的抑制劑。它與索磷布韋聯合使用，用於治療所有六種主要基因型的C型肝炎感染。

副作用
在進行研究期間使用此藥物的副作用發生頻率與接受安慰劑治療的人群相似。此藥物主要經由糞便排泄（94%），尿液排泄的僅佔0.4%，整體生物半衰期約為15小時。

參見
*
*
*索磷布韋/維帕他韋

引用